NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

乳癌液態切片的全球市場

Breast Cancer Liquid Biopsy

出版商 Global Industry Analysts, Inc. 商品編碼 994489
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
乳癌液態切片的全球市場 Breast Cancer Liquid Biopsy
出版日期: 2021年04月01日內容資訊: 英文 172 Pages
簡介

全球乳癌液態切片的市場規模,預計在分析期間(2020年∼2027年)將以19.9%的年複合成長率增長,從2020年的2億6,260萬美元,到2027年達到9億3,630萬美元。

本報告所分析的市場區隔之一的無細胞DNA(cfDNA)部門,在分析期間中預計將以20.1%的年複合成長率增長,達到3億8,780萬美元。

本報告提供全球乳癌液態切片市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:34公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP21384

Abstract:

Global Breast Cancer Liquid Biopsy Market to Reach $936.3 Million by 2027

Amid the COVID-19 crisis, the global market for Breast Cancer Liquid Biopsy estimated at US$262.6 Million in the year 2020, is projected to reach a revised size of US$936.3 Million by 2027, growing at a CAGR of 19.9% over the analysis period 2020-2027. Cell-Free DNA (cfDNA), one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$387.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 22.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $78.3 Million, While China is Forecast to Grow at 19.5% CAGR

The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$78.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$164.4 Million by the year 2027 trailing a CAGR of 19.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.9% and 16.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Extracellular Vesicles (EVs) Segment to Record 17.5% CAGR

In the global Extracellular Vesicles (EVs) segment, USA, Canada, Japan, China and Europe will drive the 17.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$41.3 Million in the year 2020 will reach a projected size of US$127.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$109.2 Million by the year 2027.

Select Competitors (Total 34 Featured) -

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Cell-Free DNA (cfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Cell-Free DNA (cfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cell-Free DNA (cfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Extracellular Vesicles (EVs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Extracellular Vesicles (EVs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Extracellular Vesicles (EVs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Other Circulating Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Other Circulating Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Circulating Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Hospitals & Physician Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 85: Rest of Europe Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 88: Asia-Pacific Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 91: Asia-Pacific Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 94: Rest of World Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Cell-Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs) and Other Circulating Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of World Current & Future Analysis for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of World Historic Review for Breast Cancer Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of World 15-Year Perspective for Breast Cancer Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 34